



Manufacturer's Information

Test No. 15-5671: Urine Drug Analysis

The sample sets contained urine samples from three cases, each with an individual case scenario. Each case sample consisted of one specimen bottle containing 50mL of human urine. Participants were requested to analyze the urine samples and report the presence of any drugs/metabolites, any quantitative data obtained (including uncertainty), methods used, and any additional comments.

SAMPLE PREPARATION-

The urine used in this test was from the same lot, which tested negative for a variety of common drugs and controlled substances prior to being obtained from a commercial supplier.

A stock solution of each drug was used to spike each item. These solutions were obtained in sealed ampoules and were not opened until needed for production. Items were prepared at separate times using the following procedure, and different glassware was used for each item.

ITEMS 1, 2, and 3 (PREPARATION): Sample preparation consisted of adding a predetermined amount of drug stock solution to a beaker containing human urine, where the equivalent of 2% w/v sodium fluoride was added and then stirred with a magnetic stirrer for at least 20 minutes. 50mL of the mixture was then transferred into each of the pre-labeled specimen bottles. All bottles were stored in a refrigerator immediately after production until the sample sets were prepared.

SAMPLE SET ASSEMBLY: Each sample set contained Items 1, 2, and 3 and was placed into a Department of Transportation regulated shipping container. Each sample pack was labeled and returned to the refrigerator until shipment.

VERIFICATION-

Two out of three of the laboratories that conducted predistribution analysis of the samples reported the expected drugs and/or a minimum of one expected metabolite per drug. One laboratory did not report 11-nor-9-carboxy- Δ^9 -THC for Item 1. After an investigation, CTS determined that the samples were acceptable and released the test.

<u>Item 1 Drug (Concentration)</u>	<u>Item 2 Drug (Concentration)</u>	<u>Item 3 Drug (Concentration)</u>
Alprazolam (300ng/mL)	Benzoyllecgonine (2000ng/mL)	Fentanyl (75ng/mL)
Alpha-hydroxyalprazolam (400ng/mL)	Ecgonine methyl ester (400ng/mL)	Norfentanyl (260ng/mL)
11-nor-9-carboxy- Δ^9 -THC (100ng/mL)		

Please note that the Preparation Concentration is the value used for calculations during the test preparation phase and may not necessarily represent the final concentration of the samples. It is advised to wait for the Grand Mean statistics available in the Summary Report before evaluating performance.

The information presented here details how test samples were prepared as well as any design specifications. This information does not necessarily represent the answers that should or could be obtained from an examination of the sample(s). Final interpretation of the results should be deferred until the summary report is available.